Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs BioNTech SE - ADR — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.52, while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AMDY | BNTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $119.34 |
52-Week Low | $29.80 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.90, up 3.01% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, including $0.68 on August 5, 2026, but key valuation ratios like P/E and P/S are unavailable. Recent news highlights high yield potential but cautions on net asset value erosion amid AMD stock volatility.
Outlook hinges on AMD's performance; the ETF offers income via call spreads but faces NAV decline risks if AMD rallies sharply. Investors should weigh high distributions against potential capital depreciation, with sentiment mixed among analysts citing sustainability concerns.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
